Views & Analysis Recent trends in ANDA litigation Sheila Swaroop and Kaitlin Heinen examine the findings of a recent report.
News BMS settles US off-label marketing case for $19.5m BMS illegally promoted schizophrenia drug, says attorney general
News Pfizer fined £84m for exploiting epilepsy drug price Pfizer hiked price by 2600%, says competition watchdog.
UK & Europe Pfizer's Lyrica patent appeal fails in UK Generics firms free to exploit gap in Pfizer's patent defences.
News Andexxa reaches the end of the line in the US AstraZeneca will voluntarily take its anticoagulant reversal agent Andexxa off the market in the US amid reports of serious clotting side effects.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
